|
|
 |
|
Viewing report
|
|
|
|
The Future of Metabolomics: Building Competitive Advantage in Drug Discovery, Clinical Development and Diagnostics
Business Insights, Aug 2006, Pages: 156
Metabolomics - the new ‘omics’ - is a dynamic and emerging field, joining genomics, transcriptomics and proteomics in enabling an integrative systems biology approach to drug discovery and development. Although metabolomics is still at an early evolutionary stage it is forecast that over the next decade the biopharma industry will apply this technology more widely in drug development and data obtained will be used in drug filing and optimizing the lifecycle management of marketed drugs.
'The Future of Metabolomics' provides detailed insight into the effective use of metabolomics throughout drug discovery, preclinical development and clinical trials. The report also highlights the use of metabolomics in maximizing and sustaining revenues post-marketing and in the development of clinical diagnostics. Use up-to-date case studies to understand current and future directions in the application of metabolomics to drug discovery and development, explore potential cost savings, and recognize lucrative partnering opportunities in this fast moving field.
Key Features:
- An update on how regulatory authorities in the US and Europe are preparing for the use of metabolomics and biomarker data in drug submissions.
- In-depth case studies on how leading metabolomics innovators and pharmaceutical companies are applying metabolomics at all stages of the drug and diagnostic development process.
- Analysis of the platform technology, service and bioinformatics companies at the forefront of the metabolomics market.
- A detailed breakdown of the potential of metabolomics to reduce costs, time and attrition rates in drug discovery and clinical development.
Key Findings:
- Future growth of the metabolomics market will be driven by three areas: biomarker discovery services, the
application of bioinformatics/chemometrics and the development of technology platforms, leading to a market size
of over US $2 billion by 2012.
- Metabolomics can be applied in lifecycle management by identifying new indications for a marketed product, or by developing a test that will optimize dosing and help patients to receive a dose that is both efficacious and safe.
- Metabolomics can be used to uncover new drug targets, prioritize lead compounds, and assess toxicity non-invasively, enabling the development of novel, smarter and safer drugs.
- Within the next 10 years it is anticipated that metabolomics will become a standard tool in the pharma industry as validated metabolomic-based biomarkers begin to emerge and cost-effective screens are established.
Customers who bought this item also bought
Metabolomics 2008
Solving Drug Discovery with Metabolomics and Metabonomics: New Aspects of the Omic Revolution
Metabolomics: The Next Omics Technology for the Diagnostics Industry
Companion Biomarkers in Drug Development
Commercial Opportunities from Biomarkers: Transforming drug discovery, clinical development and molecular diagnostics
Biomarkers - Technologies, Markets and Companies
Biomarkers 2008
Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
Innovations in Bioinformatics: Emerging Tools for Drug Discovery and Development
Genomics in Drug Discovery and Development
Advances in Lab-on-Chip and Microfluidics Technologies for Drug Discovery and Clinical Diagnostics
The Future of Systems Biology: Emerging Technologies and their Impact on Drug Discovery, Development and Diagnostics
|
|
|
|
